Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

NCT07612280 is registered in ClinicalTrials.gov with Jubilant Therapeutics Inc. as lead sponsor.

NCT NCT07612280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Lead sponsor
Jubilant Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 21, 2024
Completion date
September 15, 2028
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia (et), myelodysplastic/myeloproliferative neoplasms (mds/mpn), myeloproliferative neoplasms (mpn)